SLC9A3R1 - New-wiki

Interactant Symbol	Name	Associated Pathways Hide	Binding Drugs Hide	Associated Diseases Hide
CRABP1	cellular retinoic acid binding protein 1	RA biosynthesis pathway
CTNNB1	catenin beta 1	Degradation of beta-catenin by the destruction complex Beta-catenin phosphorylation cascade TCF dependent signaling in response to WNT Formation of the beta-catenin:TCF transactivating complex Formation of the beta-catenin:TCF transactivating complex LRR FLII-interacting protein 1 (LRRFIP1) activates type I IFN production Apoptotic cleavage of cell adhesion proteins Deactivation of the beta-catenin transactivating complex Synthesis, secretion, and inactivation of Glucagon-like Peptide-1 (GLP-1) Ca2+ pathway Adherens junctions interactions Binding of TCF/LEF:CTNNB1 to target gene promoters Disassembly of the destruction complex and recruitment of AXIN to the membrane Disassembly of the destruction complex and recruitment of AXIN to the membrane VEGFR2 mediated vascular permeability Myogenesis Myogenesis Signaling by GSK3beta mutants S33 mutants of beta-catenin aren't phosphorylated S37 mutants of beta-catenin aren't phosphorylated S45 mutants of beta-catenin aren't phosphorylated T41 mutants of beta-catenin aren't phosphorylated RHO GTPases activate IQGAPs Transcriptional Regulation by VENTX InlA-mediated entry of Listeria monocytogenes into host cells RUNX3 regulates WNT signaling	Urea	Gastric cancer Colorectal cancer Endometrial Cancer Pilomatricoma; Epithelioma calcificans of Malherbe Thyroid cancer Hepatocellular carcinoma
DLGAP4	DLG associated protein 4	Neurexins and neuroligins Neurexins and neuroligins
EGFR	epidermal growth factor receptor	Signaling by ERBB2 Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants Signaling by ERBB4 SHC1 events in ERBB2 signaling SHC1 events in ERBB2 signaling PLCG1 events in ERBB2 signaling PIP3 activates AKT signaling Signaling by EGFR GRB2 events in EGFR signaling GAB1 signalosome SHC1 events in EGFR signaling EGFR downregulation GRB2 events in ERBB2 signaling PI3K events in ERBB2 signaling EGFR interacts with phospholipase C-gamma EGFR Transactivation by Gastrin Constitutive Signaling by Aberrant PI3K in Cancer Signal transduction by L1 Constitutive Signaling by EGFRvIII Inhibition of Signaling by Overexpressed EGFR RAF/MAP kinase cascade ERBB2 Regulates Cell Motility PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling ERBB2 Activates PTK6 Signaling Cargo recognition for clathrin-mediated endocytosis Clathrin-mediated endocytosis PTK6 promotes HIF1A stabilization Downregulation of ERBB2 signaling TFAP2 (AP-2) family regulates transcription of growth factors and their receptors Extra-nuclear estrogen signaling NOTCH3 Activation and Transmission of Signal to the Nucleus HCMV Early Events Estrogen-dependent nuclear events downstream of ESR-membrane signaling Signaling by ERBB2 KD Mutants Signaling by ERBB2 ECD mutants Signaling by ERBB2 TMD/JMD mutants	Cetuximab Lidocaine Gefitinib Erlotinib Lapatinib Panitumumab Alvocidib IGN311 Matuzumab Vandetanib Rindopepimut Canertinib Pelitinib Varlitinib AV-412 S-{3-[(4-ANILINOQUINAZOLIN-6-YL)AMINO]-3-OXOPROPYL}-L-CYSTEINE PD-168393 Afatinib Osimertinib Necitumumab Foreskin keratinocyte (neonatal) Depatuxizumab mafodotin Icotinib Neratinib Dacomitinib Fostamatinib Zalutumumab Brigatinib Olmutinib Zanubrutinib Abivertinib	Choriocarcinoma Gastric cancer Bladder cancer Oral cancer Glioma Laryngeal cancer Cervical cancer Esophageal cancer
EZR	ezrin	Netrin-1 signaling Recycling pathway of L1 Recycling pathway of L1
GNA11	G protein subunit alpha 11	Acetylcholine regulates insulin secretion Acetylcholine regulates insulin secretion G alpha (q) signalling events G alpha (q) signalling events ADP signalling through P2Y purinoceptor 1 ADP signalling through P2Y purinoceptor 1 Thromboxane signalling through TP receptor Fatty Acids bound to GPR40 (FFAR1) regulate insulin secretion Fatty Acids bound to GPR40 (FFAR1) regulate insulin secretion Thrombin signalling through proteinase activated receptors (PARs)
GNAQ	G protein subunit alpha q	Acetylcholine regulates insulin secretion Acetylcholine regulates insulin secretion G alpha (q) signalling events G alpha (q) signalling events ADP signalling through P2Y purinoceptor 1 ADP signalling through P2Y purinoceptor 1 Thromboxane signalling through TP receptor Fatty Acids bound to GPR40 (FFAR1) regulate insulin secretion Fatty Acids bound to GPR40 (FFAR1) regulate insulin secretion Thrombin signalling through proteinase activated receptors (PARs)
GRK6	G protein-coupled receptor kinase 6	G alpha (s) signalling events
KCNJ1	potassium inwardly rectifying channel subfamily J member 1	Potassium transport channels	Bethanidine Glimepiride Minoxidil Acetohexamide Tolbutamide Glymidine Yohimbine Agmatine Butamben	Bartter syndrome
LHCGR	luteinizing hormone/choriogonadotropin receptor	Hormone ligand-binding receptors G alpha (s) signalling events ADORA2B mediated anti-inflammatory cytokines production	Goserelin Menotropins Lutropin alfa Cetrorelix Choriogonadotropin alfa Buserelin Chorionic Gonadotropin (Human)	46,XY disorders of sex development (Disorders in androgen synthesis or action), including: Congenital adrenal hyperplasias; Leydig cell hypoplasia; Androgen insensitivity syndrome (AIS) Premature ovarian failure Precocious puberty, including: Central precocious puberty (CEPREPU); Familial male precocious puberty (FMPP)
LPAR2	lysophosphatidic acid receptor 2	G alpha (q) signalling events G alpha (i) signalling events Lysosphingolipid and LPA receptors
MSN	moesin	Recycling pathway of L1 Recycling pathway of L1 Gene and protein expression by JAK-STAT signaling after Interleukin-12 stimulation
NF2	neurofibromin 2	Regulation of actin dynamics for phagocytic cup formation RHO GTPases activate PAKs		Malignant pleural mesothelioma Noonan syndrome and related disorders, including: Noonan syndrome (NS); Leopard syndrome (LS); Noonan syndrome-like with loose anagen hair (NS/LAH); CBL-mutation associated syndrome (CBL); Neurofibromatosis type 1 (NF1); Neurofibromatosis type 2 (NF2); Neurofibromatosis-Noonan syndrome (NFNS); Legius syndrome; Cardiofaciocutaneous syndrome (CFCS); Costello syndrome (CS)
NOS2	nitric oxide synthase 2	ROS and RNS production in phagocytes Nitric oxide stimulates guanylate cyclase Interleukin-4 and Interleukin-13 signaling Peroxisomal protein import Peroxisomal protein import Inhibition of nitric oxide production	Arginine Citrulline Minocycline Miconazole Dexamethasone N,N-dimethylarginine 4R-Fluoro-N6-ethanimidoyl-L-lysine 3-Bromo-7-Nitroindazole N-[3-(aminomethyl)benzyl]acetamidine 7-Nitroindazole S-Ethylisothiourea Thiocoumarin N-omega-propyl-L-arginine 6-Nitroindazole N(5)-[(hydroxyamino)(imino)methyl]-L-ornithine Imidazole N-(4-{2-[(3-chlorobenzyl)amino]ethyl}phenyl)thiophene-2-carboximidamide Thiocitrulline L-erythro-7,8-dihydrobiopterin 5-Nitroindazole KD7040 Fenoxaprop-ethyl Pimagedine 5-(4'-AMINO-1'-ETHYL-5',8'-DIFLUORO-1'H-SPIRO[PIPERIDINE-4,2'-QUINAZOLINE]-1-YLCARBONYL)PICOLINONITRILE N-[2-(1,3-BENZODIOXOL-5-YL)ETHYL]-1-[2-(1H-IMIDAZOL-1-YL)-6-METHYLPYRIMIDIN-4-YL]-D-PROLINAMIDE 4-({4-[(4-methoxypyridin-2-yl)amino]piperidin-1-yl}carbonyl)benzonitrile (2S)-2-methyl-2,3-dihydrothieno[2,3-f][1,4]oxazepin-5-amine (3R)-3-[(1,2,3,4-tetrahydroisoquinolin-7-yloxy)methyl]-2,3-dihydrothieno[2,3-f][1,4]oxazepin-5-amine 4-(1,3-BENZODIOXOL-5-YLOXY)-2-[4-(1H-IMIDAZOL-1-YL)PHENOXY]PYRIMIDINE (3S)-1-(1,3-BENZODIOXOL-5-YLMETHYL)-3-[4-(1H-IMIDAZOL-1-YL)PHENOXY]PIPERIDINE 4-(1,3-BENZODIOXOL-5-YLOXY)-2-[4-(1H-IMIDAZOL-1-YL)PHENOXY]-6-METHYLPYRIMIDINE ETHYL 4-[(4-CHLOROPYRIDIN-2-YL)AMINO]PIPERIDINE-1-CARBOXYLATE N-[2-(4-AMINO-5,8-DIFLUORO-1,2-DIHYDROQUINAZOLIN-2-YL)ETHYL]-3-FURAMIDE ETHYL 4-[(4-METHYLPYRIDIN-2-YL)AMINO]PIPERIDINE-1-CARBOXYLATE N-[2-(6-AMINO-4-METHYLPYRIDIN-2-YL)ETHYL]-4-CYANOBENZAMIDE 1-(6-CYANO-3-PYRIDYLCARBONYL)-5',8'-DIFLUOROSPIRO[PIPERIDINE-4,2'(1'H)-QUINAZOLINE]-4'-AMINE 4-(1H-IMIDAZOL-1-YL)PHENOL 1-[4-(AMINOMETHYL)BENZOYL]-5'-FLUORO-1'H-SPIRO[PIPERIDINE-4,2'-QUINAZOLIN]-4'-AMINE Triflusal Levamlodipine Dipyrithione Dexamethasone acetate	Esophageal cancer
OPRK1	opioid receptor kappa 1	Peptide ligand-binding receptors G alpha (i) signalling events MECP2 regulates neuronal receptors and channels	Tramadol Atomoxetine Morphine Codeine Amitriptyline Hydromorphone Mirtazapine Progesterone Meperidine Oxycodone Dextromethorphan Lamotrigine Butorphanol Dextropropoxyphene Pentazocine Naltrexone Sufentanil Fentanyl Levomenthol Loperamide Nalbuphine Levorphanol Remifentanil Buprenorphine Naloxone Dezocine Ketamine Aripiprazole 3-Methylthiofentanyl Diamorphine Etorphine Carfentanil Diprenorphine Dihydromorphine 3-Methylfentanyl V1003 Asimadoline CR665 ADL 10-0101 Mianserin Tapentadol Nalmefene Alvimopan Morphine glucuronide Ketobemidone Methylnaltrexone Butyrfentanyl Pholcodine Eluxadoline Opium Pentoxyverine Naldemedine Loxicodegol
P2RY1	purinergic receptor P2Y1	G alpha (q) signalling events P2Y receptors ADP signalling through P2Y purinoceptor 1 ADP signalling through P2Y purinoceptor 1	Promethazine
PAG1	phosphoprotein membrane anchor with glycosphingolipid microdomains 1	GAB1 signalosome Phosphorylation of CD3 and TCR zeta chains
PDGFRA	platelet derived growth factor receptor alpha	PIP3 activates AKT signaling Downstream signal transduction Signaling by PDGF Constitutive Signaling by Aberrant PI3K in Cancer RAF/MAP kinase cascade PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants Signaling by PDGFRA extracellular domain mutants Imatinib-resistant PDGFR mutants Sunitinib-resistant PDGFR mutants Regorafenib-resistant PDGFR mutants Sorafenib-resistant PDGFR mutants PDGFR mutants bind TKIs	Becaplermin Imatinib Sunitinib XL820 Olaratumab Pazopanib Midostaurin Regorafenib Ponatinib Lenvatinib Nintedanib Foreskin keratinocyte (neonatal) Fostamatinib Erdafitinib Amuvatinib Ripretinib	Glioma
PDGFRB	platelet derived growth factor receptor beta	PIP3 activates AKT signaling Downstream signal transduction Signaling by PDGF Constitutive Signaling by Aberrant PI3K in Cancer RAF/MAP kinase cascade PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling	Becaplermin Sorafenib Imatinib Dasatinib Sunitinib XL999 XL820 Pazopanib Midostaurin Regorafenib Nintedanib Polaprezinc Trapidil Foreskin fibroblast (neonatal) Fostamatinib Erdafitinib Pexidartinib Ripretinib Pralsetinib	Glioma
PDZK1	PDZ domain containing 1

Search Results for: SLC9A3R1